These results suggested that bufalin reversed HGF-induced EGFR-TKIs resistance in EGFR mutant lung cancer cells by inhibiting the phosphorylation of Met and the downstream PI3K/Akt, and Met could be one of the therapeutic targets of bufalin. The gene discussed is AKT1; the disease is lung carcinoma.